Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity - PubMed (original) (raw)
Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity
H G Kräusslich. Proc Natl Acad Sci U S A. 1991.
Abstract
Enzymatically active retroviral proteinases are dimers of identical polypeptide chains with a fold similar to that of other aspartic proteinases. Each polypeptide chain, encoded on one of the viral polyproteins, is less than half the size of cellular aspartic proteinases and contains only one of the two active-site aspartate residues. A plasmid was constructed to generate a genetically linked dimer of the proteinase (PR) of human immunodeficiency virus (HIV) type 1, composed of two copies of the PR sequence linked by a structurally flexible hinge region. The expression product was stable and active against HIV polyprotein substrates. Mutational analysis revealed that the linked dimer, and not multimers thereof, contained the proteolytic activity. Expression of the linked dimer as a component of a HIV polyprotein by in vitro translation gave rapid autocatalytic processing, whereas the wild-type polyprotein was stable on prolonged incubation. Transfection of HIV subviral or proviral constructs, containing the linked dimer of HIV PR, gave premature processing of the viral polyproteins, thus preventing particle formation and infectivity. Premature processing also led to increased cell toxicity.
Similar articles
- Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.
Rosé JR, Babé LM, Craik CS. Rosé JR, et al. J Virol. 1995 May;69(5):2751-8. doi: 10.1128/JVI.69.5.2751-2758.1995. J Virol. 1995. PMID: 7535864 Free PMC article. - An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.
Konvalinka J, Litterst MA, Welker R, Kottler H, Rippmann F, Heuser AM, Kräusslich HG. Konvalinka J, et al. J Virol. 1995 Nov;69(11):7180-6. doi: 10.1128/JVI.69.11.7180-7186.1995. J Virol. 1995. PMID: 7474139 Free PMC article. - A role for the aspartyl protease from the human immunodeficiency virus type 1 (HIV-1) in the orchestration of virus assembly.
Navia MA, McKeever BM. Navia MA, et al. Ann N Y Acad Sci. 1990;616:73-85. doi: 10.1111/j.1749-6632.1990.tb17829.x. Ann N Y Acad Sci. 1990. PMID: 2078037 Review.
Cited by
- HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation.
Hsieh SH, Yu FH, Huang KJ, Wang CT. Hsieh SH, et al. J Virol. 2023 Sep 28;97(9):e0094823. doi: 10.1128/jvi.00948-23. Epub 2023 Sep 6. J Virol. 2023. PMID: 37671867 Free PMC article. - Structure of the HIV immature lattice allows for essential lattice remodeling within budded virions.
Guo S, Saha I, Saffarian S, Johnson ME. Guo S, et al. Elife. 2023 Jul 12;12:e84881. doi: 10.7554/eLife.84881. Elife. 2023. PMID: 37435945 Free PMC article. - Neutral sphingomyelinase 2 is required for HIV-1 maturation.
Waheed AA, Zhu Y, Agostino E, Naing L, Hikichi Y, Soheilian F, Yoo SW, Song Y, Zhang P, Slusher BS, Haughey NJ, Freed EO. Waheed AA, et al. Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2219475120. doi: 10.1073/pnas.2219475120. Epub 2023 Jul 5. Proc Natl Acad Sci U S A. 2023. PMID: 37406093 Free PMC article. - Viral proteases as therapeutic targets.
Majerová T, Konvalinka J. Majerová T, et al. Mol Aspects Med. 2022 Dec;88:101159. doi: 10.1016/j.mam.2022.101159. Epub 2022 Nov 29. Mol Aspects Med. 2022. PMID: 36459838 Free PMC article. Review. - Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs.
Kim JG, Shan L. Kim JG, et al. Viruses. 2022 May 28;14(6):1179. doi: 10.3390/v14061179. Viruses. 2022. PMID: 35746649 Free PMC article. Review.
References
- Cell. 1987 Apr 24;49(2):221-7 - PubMed
- J Virol. 1986 Aug;59(2):284-91 - PubMed
- Gene. 1987;56(1):125-35 - PubMed
- Nature. 1988 Jan 21;331(6153):280-3 - PubMed
- J Virol. 1988 May;62(5):1808-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials